Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen by Lewis, Michelle et al.
Toxins 2010, 2, 1825-1847; doi:10.3390/toxins2071825 
 
toxins
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Article 
Identification of Small Molecule Inhibitors of Clostridium 
perfringens ε-Toxin Cytotoxicity Using a Cell-Based  
High-Throughput Screen  
Michelle Lewis 
1, Charles David Weaver 
1,2 and Mark S. McClain 
3,* 
1  Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37235, USA;  
E-Mail: michelle.lewis@vanderbilt.edu  
2  Department of Pharmacology, Vanderbilt University, Nashville, TN 37235, USA;  
E-Mail: david.weaver@vanderbilt.edu  
3  Department of Medicine, Vanderbilt University, Nashville, TN 37235, USA 
*  Author to whom correspondence should be addressed; E-Mail: mark.mcclain@vanderbilt.edu;  
Tel.: +1-615-322-2035; Fax: +1-615-343-6160. 
Received: 14 May 2010; in revised form: 23 June 2010 / Accepted: 6 July 2010 /  
Published: 9 July 2010  
 
Abstract: The Clostridium perfringens epsilon toxin, a select agent, is responsible for a 
severe, often fatal enterotoxemia characterized by edema in the heart, lungs, kidney, and 
brain. The toxin is believed to be an oligomeric pore-forming toxin. Currently, there is no 
effective therapy for countering the cytotoxic activity of the toxin in exposed individuals. 
Using a robust cell-based high-throughput screening (HTS) assay, we screened a   
151,616-compound library for the ability to inhibit ε-toxin-induced cytotoxicity. Survival 
of MDCK cells exposed to the toxin was assessed by addition of resazurin to detect 
metabolic activity in surviving cells. The hit rate for this screen was 0.6%. Following a 
secondary screen of each hit in triplicate and assays to eliminate false positives, we focused 
on three structurally-distinct compounds: an N-cycloalkylbenzamide, a furo[2,3-b]quinoline, 
and a 6H-anthra[1,9-cd]isoxazol. None of the three compounds appeared to inhibit toxin 
binding to cells or the ability of the toxin to form oligomeric complexes. Additional assays 
demonstrated that two of the inhibitory compounds inhibited ε-toxin-induced permeabilization 
of MDCK cells to propidium iodide. Furthermore, the two compounds exhibited inhibitory 
effects on cells pre-treated with toxin. Structural analogs of one of the inhibitors identified 
through the high-throughput screen were analyzed and provided initial structure-activity 
data. These compounds should serve as the basis for further structure-activity refinement 
that may lead to the development of effective anti-ε-toxin therapeutics. 
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1. Introduction 
The C. perfringens ε-toxin is a potent bacterial protein toxin, with an LD50 in mice on the order of 
100 ng per kg [1,2], and is categorized by the US Department of Health and Human Services as a 
select agent. The ε-toxin is responsible for a severe enterotoxemia primarily in livestock animals but 
may also be toxic to humans [3–7]. As is true of many select agents and toxins, human exposure to  
ε-toxin appears to be rare. Pathologic changes are observed primarily in the brains and kidneys of 
animals intoxicated by ε-toxin [8–10], but edema of the heart and lungs is also common.  
Following interaction with sensitive cells, ε-toxin assembles into heptameric oligomers [11,12]. 
Evidence from multiple studies suggests that these ε-toxin oligomers form pores in the plasma 
membrane of cells. Addition of purified toxin to cells is followed rapidly by efflux of intracellular K
+ 
and increases in intracellular Cl
− and Na
+ [13,14]. MDCK cells treated with ε-toxin become permeable 
to fluorescent dyes including propidium iodide and 7-aminoactinomycin D (7-AAD), with a strong 
correlation between the kinetics of dye entry and loss of cell viability [14–16]. Experiments using 
artificial lipid bilayers confirmed the channel-forming properties of the toxin [14], and there is no 
evidence that ε-toxin enters cells [13,17,18]. Thus, it is widely believed that ε-toxin acts by forming 
ion-permeable pores in the plasma membrane of sensitive cells.  
Both a vaccine and anti-toxin immune sera are approved for veterinary use in the protection of 
economically-important livestock, where (for example) ε-toxin may account for over 20% of deaths 
among feedlot sheep [19]. However, neither the vaccine nor the anti-toxin immune sera is effective at 
treating animals intoxicated by ε-toxin and no therapy for ε-toxin-related illness is approved for human 
use. The veterinary vaccine is effective at providing immunity to the toxin, though a series of booster 
immunizations may be required to confer long-term immunity [20]. Anti-toxin immune sera may also 
be used to protect immunologically naïve animals. However, in the event that an animal exhibits 
symptoms of intoxication by ε-toxin, it is typically too late for the current anti-toxin to be effective and 
use of the anti-toxin is typically limited to prophylactic treatment of unvaccinated animals within a 
herd [21]. Thus, both of the existing approaches to combat ε-toxin that are approved for veterinary use 
are of limited value in treating individuals exposed to ε-toxin. Alternative countermeasures are needed 
that inhibit the activity of the toxin. Unlike existing vaccine and antitoxin therapies, a small molecule 
inhibitor may be effective in inhibiting ε-toxin after the toxin has bound to cells by blocking the  
pore-forming properties of the toxin or by blocking a host response that leads to cell death. Such an 
inhibitor could be an effective treatment for individuals exposed to the toxin. 
In this study, we carried out a high-throughput cell-based screen to identify small molecule 
inhibitors of the C. perfringens ε-toxin. The inhibitory activities of these compounds and structural 
analogs were verified using a variety of different measures of cytotoxic activity. Toxins 2010, 2  
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2. Materials and Methods 
2.1. Cell culture 
MDCK cells (ATCC) were routinely cultured in MEM supplemented with glutamax (Invitrogen) 
and 10% fetal clone III (HyClone) and incubated at 37 °C in 5% CO2. Cells were subcultured by 
diluting two-fold into fresh medium 16 to 24 hours prior to cytotoxicity screens. 
2.2. Recombinant ε-toxin expression and purification 
The gene encoding ε-prototoxin, etxB, was fused to a carboxy-terminal 6-His tag and cloned into 
pET22b [22]. The ε-prototoxin expressing plasmid was transformed into NovaBlue (DE3) (Novagen), 
along with the plasmid pLysE (encoding bacteriophage T7 lysozyme) and transformants were grown 
in broth supplemented with antibiotics to an optical density at 600 nm of 0.7. Isopropyl   
β-D-thiogalactopyranoside then was added to a final concentration of 1 mM to induce expression of 
the cloned gene, and the cultures were grown for another 3 h. The cells were collected and 
resuspended in 1/20th culture volume of B-PER Bacterial Protein Extraction Reagent (Pierce) 
supplemented with Complete Mini protease inhibitor cocktail (EDTA-free, Roche), and mixed for 
10 minutes at room temperature. The cell debris was pelleted, and the supernatant was recovered. The 
B-PER extracted material was diluted four-fold with water, and applied to a Q-Sepharose column. The 
ε-prototoxin-containing flow-through material was collected and applied to a Ni-NTA affinity column 
(Qiagen). The Ni-NTA column was washed with a buffer comprised of 20 mM sodium phosphate, 
300 mM sodium chloride, and 20 mM imidazole (pH 8.0), and the ε-prototoxin was eluted in a buffer 
comprised of 20 mM sodium phosphate, 300 mM sodium chloride, and 250 mM imidazole (pH 8.0). 
The identification of the ε-prototoxin protein in the purified sample was confirmed by immunoblotting 
with an ε-toxin-specific monoclonal antibody [23]. A derivative plasmid that expressed a GFP-ε-toxin 
fusion protein was also used [21]. Protein concentrations were determined using micro-BCA (Pierce). 
2.3. Compound library 
A compound library consisting of 151,616 compounds represents a diverse subset of the >1 million 
member inventories of two companies, ChemDiv and ChemBridge. Each chemical is dissolved at a 
concentration of 10 mM in dimethylsulfoxide. Confirmed hits and their structural analogs were 
acquired from commercial sources (ChemDiv, ChemBridge, and Specs) as dry powders and dissolved 
in DMSO. 
2.4. High-throughput screen for ε-toxin inhibitors 
Assays were performed using black, clear bottom 384-well plates (Greiner Bio-One). Compounds 
(10 nL of 10 mM stock solutions in DMSO) were dispensed using an Echo 550 non-contact liquid 
handler (Labcyte). Medium (10 μL phenol red-free Leibovitz L-15 supplemented with glutamax) was 
added to each well using a Multidrop liquid handler (Thermo Electron). The assay plates then were 
transported to a biological containment lab for further processing. Toxins 2010, 2  
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Within the biological containment lab, 10 μL of 5 × 10
5 MDCK cells per mL (in phenol red-free 
Leibovitz L-15 medium supplemented with glutamax, 10% fetal clone III, and antibiotic-antimycotic 
solution (Invitrogen)) were added to the wells of the assay plates using a BioTek μFill dispenser. 
Purified recombinant ε-toxin (in Leibovitz L-15, 10 μL per well, at a final concentration of 10 nM) 
then was added to each well using a BioTek μFill dispenser. Plates were incubated at 37 °C for  
16 hours. Cytotoxicity was assessed by detecting metabolically active cells. CellTiter Blue reagent  
(10 μL per well, Promega) was added to the assay plates, and the plates were incubated at 37 °C for an 
additional 4 hours. Fluorescence at 590 nm was measured following excitation at 560 nm using a 
BioTek FLx800 plate reader. Control plates lacking library compounds were included at the beginning 
and end of each set of assay plates. One half of each control plate received medium without toxin  
(i.e., cells only) whereas the remaining halves of each control plate received medium containing toxin. 
If Z’ for either of the two control plates was less than 0.5, the data set was discarded and the 
compounds were re-evaluated [24]. 
2.5. Secondary screens  
Compounds that appeared to inhibit ε-toxin-induced cytotoxicity in the primary HTS were re-tested 
in triplicate as described above, except that the ε-toxin concentration was increased to 20 nM. 
Compounds exhibiting the greatest apparent inhibitory activity upon re-testing in triplicate were 
examined for non-specific assay interference by adding the compounds to cells in the absence of  
ε-toxin. Compounds that led to a significant increase in fluorescence at 590 nm were excluded from 
further study. 
2.6. Immunoblotting 
Protein samples in SDS sample buffer were heated in a boiling water bath for 5 min before analysis 
by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were developed using   
anti-GFP (Santa Cruz Biotechnology, SC-9996) or anti-beta-actin (Abcam, ab8227) antibodies 
followed by horseradish peroxidase-conjugated secondary antibodies. SuperSignal West Femto or 
SuperSignal West Pico substrates (Pierce) were used for enhanced chemiluminescent detection. 
2.7. Propidium iodide influx 
MDCK cells (10
4 cells per well) were plated in black, clear-bottomed 96-well plates. Propidium 
iodide (5 μg per mL, final concentration), ε-toxin, and inhibitory compounds were added (as 
appropriate) to the cells and fluorescence at 645 nm was measured following excitation at 485 nm 
using a BioTek FLx800 plate reader at 37 °C. 
2.8. Select agent 
Plasmid DNA capable of expressing the ε-prototoxin (or ε-toxin) is considered a select agent by the 
U.S. Department of Health and Human Services. Toxins 2010, 2  
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3. Results and Discussion 
3.1. Assay validation  
We  modified an MTT-based assay used to determine ε-toxin-induced cytotoxicity for use in a   
high-throughput screen (HTS) [22,25]. We scaled the assay to use 384-well plates instead of 96-well 
plates, and replaced the colorimetric indicator MTT with the fluorescent metabolic indicator resazurin 
(CellTiter Blue, Promega) [22]. Metabolically-active cells reduce resazurin to the fluorescent 
compound resorufin. Preliminary experiments were used to maximize the dynamic range (difference in 
fluorescence between toxin-treated and untreated MDCK cells) of the assay by determining the 
optimal number of cells per well and dose of ε-toxin needed to kill greater than 90% of the cells.  
Well-to-well variability of the assay was minimized through the use of automated fluid dispensers. To 
assess the suitability of the assay for use in a HTS, MDCK cells were dispensed into 384-well plates. 
Medium alone or medium containing purified ε-toxin then was added to the cells and cytotoxicity was 
assessed as described. A statistic, the Z' factor, accounts for both the dynamic range and the amount of 
variability in an assay, and is frequently used to assess assay performance [24]. Assays with Z' factors 
between 0.5 and 1 are typically considered to be excellent assays and to be suitable for HTS. Using 
control plates containing MDCK cells in medium alone and MDCK cells treated with ε-toxin, the 
modified assay routinely exhibits Z' values greater than 0.5 (Figure 1). Additional experiments 
demonstrated that this assay is insensitive to DMSO (the solvent in which the small drug-like 
molecules have been dissolved) concentrations up to 1% (data not shown).  
Figure 1. Assay validation. MDCK cells were treated with purified ε-toxin (■) or with 
medium alone (□) and incubated for 16 hours at 37 °C. CellTiter Blue then was added, and 
the cells incubated for an additional 4 hours. The fluorescent signal then was measured 
using a FLx800 plate reader. Results from two independent assays performed on different 
days were normalized to 100% (mean of cells treated with medium alone) and 0% (mean 
of cells treated with ε-toxin). Individual wells were arbitrarily assigned a sample number in 
order to plot the results. The means (solid line) and mean ± three-times the standard 
deviation (dashed line) are shown. Z’ for the combined data was 0.592.  
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3.2. High-throughput screen 
The Vanderbilt Institute of Chemical Biology HTS facility has chemical libraries from two sources, 
ChemDiv and ChemBridge. The 151,616 chemicals screened in this assay are representative of the 
chemical diversity of the larger ChemDiv and ChemBridge compound collections. To screen the 
chemical library, MDCK cells and ε-toxin were added to 384-well plates containing library 
compounds (1 compound per well) and incubated for 16 hours at 37 °C (Materials and Methods). 
CellTiter Blue reagent then was added to assess cell viability. Fractions of the library were screened on 
11 different days over a 10 week period. Each assay included control plates of cells with and without 
ε-toxin (no compounds) positioned at the beginning and end of each set of compound-containing 
plates. The mean Z' calculated from the control plates over the course of the entire screen was 0.653.  
To identify active compounds (e.g., compounds that inhibit ε-toxin cytotoxicity), raw fluorescent 
data was converted to B-scores using HTS-Corrector [26]. The B-score is an analog of the common 
practice of determining the number of standard deviations by which a signal differs from the mean 
(i.e., normal deviate or z-score), but makes minimal assumptions concerning the distribution of the 
data, corrects for row-to-row and column-to-column systematic variability by fitting a two-way 
median polish [27], and is resistant to statistical outliers [28,29]. We defined a hit as a compound that 
yielded a B-score that was more than 3 standard deviations greater than the mean B-score [28,30]. 
Using this approach, we identified 915 hits from screening the 151,616-compound library for a hit rate 
of 0.6% (Figure 2a). 
Figure 2. Compound Screening. (a) Primary HTS. Results represent the number of standard 
deviations by which the B-score for each compound differs from the mean B-score; results 
are limited to 915 out of 151616 compounds tested for which the B-score was greater than 
three standard deviations from the mean B-score. Individual compounds were arbitrarily 
assigned a sample number in order to plot the results; (b) Secondary screen. Results were 
normalized to the fluorescent signal from MDCK cells that received compounds but no  
ε-toxin (100%) and cells treated with toxin in the absence of compounds (0%). Data 
represent the mean and standard deviation of at least quadruplicate samples and are limited 
to 158 out of 915 compounds tested for which the z-score was greater than three. Individual 
compounds were arbitrarily assigned a sample number in order to plot the results. 
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3.3. Secondary screens  
Hits identified in the initial screen were retested in triplicate as a secondary screen (each compound 
was tested once in the primary HTS). The mean fluorescent signal for each compound was compared 
to the mean fluorescent signal from control wells containing MDCK cells treated with ε-toxin, but with 
no compound added. Confirmed hits were defined as compounds for which the mean fluorescent signal 
was greater than the mean signal of the control wells by greater than three standard deviations   
(i.e., z-score > 3) [28]. Results indicated that 17% (158 of 915) of the retested compounds were 
inhibitory. The low confirmation rate was likely due, at least in part, to the higher dose of toxin used in 
re-testing (Materials and Methods). The fluorescent signal from cells treated with the confirmed hits 
ranged from 4 to 84% of control (Figure 2b). Although the level of inhibition exhibited by many of 
these compounds may not be biologically relevant, the purpose of a high-throughput screen is not to 
provide drug candidates per se, but rather to provide chemical information necessary to infer   
structure-activity relationships that then will be used to develop drug candidates.  
To further study confirmed hits, the compounds were ranked by percent inhibition. Eighteen of the 
20 most active compounds were commercially available and were acquired as powders. The 
fluorescent signal from cells treated with these compounds ranged between 32 and 84% of control in 
the secondary screen. The powdered compounds were dissolved in DMSO. Because the primary and 
secondary HTS assays lacked a counterscreen to identify compounds affecting the CellTiter Blue 
assay, the acquired compounds were incubated with cells in the absence of toxin and the cells were 
treated with CellTiter Blue reagent. Compounds that led to an elevated fluorescent signal were 
considered to be false positives. The false positives included members of two distinct structural 
families, representing 11 of the 20 most active compounds (including the two most active compounds). 
Members of these two structural families were excluded from further analysis; 7 of the 18 compounds 
we acquired did not interfere with the CellTiter Blue assay.  
3.4. Analysis of confirmed hits 
We sought to determine the compound concentrations that produced minimal and maximal 
inhibition of ε-toxin-induced cytotoxicity (i.e., Imin and Imax, respectively). Based on Imin and Imax we 
could estimate the compound concentration that inhibited ε-toxin-induced cytotoxicity by 50%   
(i.e., IC50). However, due to limited solubility of the seven compounds in the tissue culture medium, 
we were unable to determine Imax. Maximum effects frequently cannot be obtained due to poor 
compound solubility [31,32]. As an alternative to compound IC50 determinations, we determined the 
extent to which a fixed dose of the compounds increased the concentration of toxin needed to kill 50% 
(CT50) of the MDCK cell monolayer. Based on these results, we selected three compounds (yielding 
the greatest increase in CT50) for further study (Figure 3). The selected compounds represent three 
distinct structural families, including an N-cylcoalkylbenzamide, a furo[2,3-b]quinoline, and a   
6H-anthra[1,9-cd]isoxazol. Each of the compounds selected for further study yielded a significant 
increase in the toxin CT50. The fluorescent signal from cells treated with these three compounds was 
51, 34, and 38% of control, respectively, in the secondary screen (Figure 2b). Toxins 2010, 2  
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Figure 3. Confirmed Hits. (a) The ChemDiv compound numbers, names, and structures of 
three confirmed hits are shown; (b) Serial dilutions of ε-toxin (25 to 0.39 nM) were added 
to MDCK cell monolayers in a 384-well plate, in the presence of 50 μM inhibitory 
compounds in 0.4% DMSO (□: compound I; ●: compound II; ○: compound III) or 0.4% 
DMSO as a control (■). After 16 hours incubation, CellTiter Blue (Promega) was added. 
Results were normalized to the fluorescent signal from MDCK cells that received 
compounds but no ε-toxin (100%) and cells treated with compounds and 0.1% Triton (0%). 
Data represent the mean and standard deviation of at least quadruplicate samples. The CT50 
values (4.7 nM, DMSO control; 7.3 nM, compound I; 6.5 nM, compound II; and 6.7 nM, 
compound III) were calculated by non-linear regression analysis. CT50 values for cells 
treated with compounds were significantly increased compared to the CT50 value of cells 
treated with the DMSO control (ANOVA followed by Dunnett's post hoc test, P < 0.05).  
 
 
We next sought to determine if the inhibitory compounds interfered with the ability of ε-toxin to 
bind to cells or to form oligomeric complexes on cells. Toxin binding and oligomerization can be 
detected by immunoblotting, though we do not have an anti-ε-toxin antibody that readily detects the 
toxin in association with MDCK cells. To overcome this obstacle, we expressed, purified, and   
trypsin-treated a GFP-tagged form of the wild-type ε-toxin [8,9,33]. This toxin retains cytotoxic 
activity, the GFP tag is not lost following trypsin treatment, and the GFP-ε-toxin fusion protein can be 
detected on cells using an anti-GFP antibody. The GFP-tagged ε-toxin was incubated with MDCK 
cells at 4 °C in the presence or absence of the inhibitory compounds for 1 hour. The cells then were 
washed to remove unbound toxin and cell lysates were prepared. An immunoblot with anti-GFP 
antibody revealed no detectable difference in the amount of ε-toxin bound to cells (data not shown). 
To determine if the inhibitory compounds disrupted the ability of ε-toxin to form oligomeric Toxins 2010, 2  
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complexes, the GFP-tagged ε-toxin was incubated with MDCK cells at 37 °C in the presence or 
absence of the inhibitory compounds for 30 minutes. Under these conditions, ε-toxin forms heat- and 
SDS-resistant oligomeric complexes believed to represent the membrane-inserted pore structure. The 
cells then were washed to remove unbound toxin and cell lysates were prepared. An immunoblot with 
anti-GFP antibody revealed no detectable difference in the ability of the GFP-tagged ε-toxin to 
assemble into oligomeric complexes (Figure 4). These results suggest that the inhibitory compounds 
interfere with either the channel formed by the toxin or with unidentified host factors that may 
contribute to ε-toxin-induced cytotoxicity. 
Figure 4. Toxin oligomerization. MDCK cells treated at 37 °C for 30 min with medium 
alone (lane 1), or medium containing GFP-tagged ε-toxin (17 nM final concentration) in 
the presence of DMSO (lane 2), 50 μM compound I (lane 3), compound II (lane 4) or 
compound III (lane 5) were washed to remove unbound toxin and lysates were prepared. 
The samples were analyzed by SDS-PAGE and immunoblotting with anti-GFP (a) or   
anti-actin (b) antibodies as a loading control. Molecular weight markers, the GFP-tagged  
ε-toxin monomer (m), and heat- and SDS-resistant oligomers of the GFP-tagged ε-toxin (o) 
are indicated. 
 
As an independent means to assess the inhibitory activity of the selected compounds, we sought to 
determine whether the compounds could interfere with ε-toxin-induced permeabilization of MDCK 
cells. Previous studies have demonstrated that the plasma membrane of cells exposed to ε-toxin 
becomes permeable to molecules up to 1 kDa in size [14,16]. This membrane permeability can be 
detected by incubating cells with propidium iodide (which is generally excluded from viable cells, and 
which exhibits a 20- to 30-fold increase in fluorescence upon binding nucleic acids) [14,15]. We first 
assessed whether the selected compounds exhibited an adverse effect on propidium iodide 
fluorescence. Cells were treated with propidium iodide in the presence of DMSO (control) or each of 
the selected compounds in the presence or absence of detergent to permeabilize the plasma membrane. 
Results indicated that compounds I and II did not interfere with the measurement of propidium iodide 
fluorescence; compound III interfered with the fluorescence of propidium iodide and was not 
evaluated for the ability to inhibit ε-toxin-induced dye uptake by MDCK cells (Figure 5a). We next 
determined whether compounds I and II inhibited the uptake of propidium iodide by MDCK cells in 
response to ε-toxin. Cells were treated with medium alone, or with toxin-containing medium 
supplemented with DMSO (control), compound I, or compound II. Results indicated that compounds I 
and II inhibited the uptake of propidium iodide by the MDCK cells (Figure 5b).  Toxins 2010, 2  
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Figure 5. Inhibition of propidium iodide influx. (a) MDCK cells in 96-well plates were 
overlayed with Leibovitz L-15 medium containing 5 μg per mL propidium iodide in the 
presence or absence of 0.1% Triton X-100 at 37 °C. Medium was supplemented with either 
DMSO (control), or compounds I, II, or III. The final concentration of compound I, II, and 
III was 50 μM, and the final DMSO concentration in all wells was 0.4%. Cells were 
incubated at 37 °C for 30 minutes. The percent change in fluorescence was calculated by 
subtracting the fluorescent signal in the absence of detergent from the fluorescent signal of 
detergent-treated samples and normalizing this net fluorescence value to the net 
fluorescence of cells treated with DMSO. Results indicate the mean and standard deviation 
of at least quadruplicate samples. The asterisk indicates results significantly different from 
the DMSO control (ANOVA followed by Dunnett's post hoc test, P < 0.05); (b) MDCK 
cells in 96-well plates were incubated in Leibovitz L-15 medium containing 5 μg per mL 
propidium iodide at 37 °C. At time zero, triplicate wells received ε-toxin and DMSO (■), 
DMSO only (□), ε-toxin and compound I (●), or ε-toxin and compound II (○). The final 
toxin concentration was 25 nM. The final concentration of compound I and compound II 
was 50 μM, and the final DMSO concentration in all wells was 0.4%. Fluorescence was 
measured at 20 minute intervals. Results represent the mean % change in fluorescence from 
the 40 minute reading (to confirm the signal had stabilized) based on triplicate samples. 
 
To further explore the inhibitory activity of the compounds, we next examined the activity of the 
inhibitors towards cells pre-treated with ε-toxin. MDCK cells were treated with ε-toxin for various 
times before the cells were washed to remove unbound toxin, and propidium iodide was added. Results 
indicated that cells became permeable to propidium iodide after being exposed to the toxin for as little 
as 5 minutes (Figure 6a). To determine whether compound I or II might be effective on cells 
previously exposed to ε-toxin, MDCK cells were treated with ε-toxin for 10 minutes before being 
washed to remove unbound toxin and fresh medium containing propidium iodide was added. The 
inhibitory compounds then were added at various times after toxin removal. Results indicated that 
compounds I and II were active when added to cells at least 10 minutes after toxin had been removed 
from the cells (Figure 6b and c).  Toxins 2010, 2  
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Figure 6. Inhibition of propidium iodide influx in cells pre-treated with ε-toxin. (a) MDCK 
cells in Leibovitz L-15 medium were treated with 25 nM ε-toxin at 37 °C for   
0 (■), 5 (□), 15 (●), 25 (○), 30 (▲), or 35 (∆) minutes before unbound toxin was washed 
away and fresh medium containing 5 μg per mL propidium iodide was added (time 0). 
Fluorescence was measured at 12 minute intervals. Results represent the mean % change in 
fluorescence from the 24 minute reading (to confirm the signal had stabilized) based on 
triplicate samples. (b) and (c) MDCK cells in Leibovitz L-15 medium were treated with  
25 nM ε-toxin at 37 °C for 10 minutes before unbound toxin was washed away and fresh 
medium containing 5 μg per mL propidium iodide was added (time 0). Medium containing 
propidium iodide and DMSO was added at time 0 (■). Medium containing propidium 
iodide and compound I (b) or compound II (c) was added at 0 (□), 5 (●), or 10 (○) minutes 
after toxin removal. The final toxin concentration was 25 nM. The final concentrations of 
compound I and compound II was 50 μM, and the final DMSO concentration in all wells 
was 0.4%. Fluorescence was measured at 20 minute intervals. Results represent the mean 
% change in fluorescence from the 20 minute reading based on triplicate samples.  
 Toxins 2010, 2  
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3.5. Structure-activity relationships 
We next sought to explore structure-activity relationships of these compounds by acquiring and 
testing a variety of structural analogs. Due to the limited availability of analogs to compounds II and III, 
we limited this analysis to analogs of compound I. Forty-three structural analogs of compound I were 
tested at 25 μM final concentration (using the CellTiter Blue assay) and z-scores were determined by 
comparison to control cells treated with ε-toxin alone (Supplemental Table 1). Seven of the analogs 
yielded z-scores greater than 3 and were considered to inhibit ε-toxin-induced cytotoxicity [28]. We 
then determined the extent to which a fixed dose of the inhibitory compounds increased the 
concentration of toxin needed to kill 50% (CT50) of an MDCK cell monolayer. Results revealed a 
variety of inhibitory activities depending on the various substitutions the core structure (Table 1).  
Table 1. Inhibitory activity of compound I and structural analogs. 
Compound 
CT50  
(25 μM) 
a 
P < 0.05  
(25 μM) 
b 
CT50  
(50 μM) 
a 
P < 0.05  
(50 μM) 
b 
 
8.1  Yes  10.1  Yes 
 
7.2  Yes  9.1  Yes 
 
7.4  Yes  8.5  Yes 
 
6.1  Yes  7.2  Yes 
 
5.9  Yes  6.7  Yes Toxins 2010, 2  
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Table 1. Cont. 
Compound 
CT50  
(25 μM) 
a 
P < 0.05  
(25 μM) 
b 
CT50  
(50 μM) 
a 
P < 0.05  
(50 μM) 
b 
 
5.8  Yes  6.6  Yes 
 
4.7  No  5.7  No 
 
5.1  No  5.7  No 
No compound  4.4  -  4.8  - 
a The inhibitory compounds were added to the medium overlying MDCK cells at either 25 or 50 μM final 
concentration. Serial dilutions of ε-toxin were added and the plates incubated for 16 hours at 37 °C. Cell 
viability was determined with CellTiter Blue as described (Materials and Methods). The CT50 of each 
compound was determined by non-linear regression analysis of quadruplicate samples at each dose of toxin.  
b The CT50 determined in the presence of each inhibitory compound was compared to the CT50 of cells treated 
with no compound (ε-toxin and DMSO vehicle control) by ANOVA followed by Dunnett’s post-hoc test. 
4. Conclusions  
Conventional therapeutics (vaccines or anti-toxin immune serum) are of limited use in the treatment 
of many toxin-mediated illnesses once an individual exhibits symptoms of toxin exposure, likely 
because the events leading to cytotoxicity have already begun [34]. New therapeutics are needed that 
can inhibit the activities of toxins that have already interacted with host cell targets. Several studies 
report identification of toxin inhibitors by screening small molecule libraries. Using direct screens for 
inhibitors of toxin activity, small molecule inhibitors have been identified that block the interaction 
between Bacillus anthracis edema factor and the host activator protein calmodulin [35], that inhibit the 
adenylate cyclase activities of edema factor and the CyaA toxin of Bordetella pertussis [36], that 
inhibit the protease activities of B. anthracis lethal factor [37] and Clostridium botulinum neurotoxin A 
[38], that inhibit the internalization of anthrax toxin [39], that inhibit intracellular transport of a variety 
of toxins acting intracellularly [40], and that inhibit the activities of ricin and Shiga toxins [41]. 
Indirectly, small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator are 
able to reduce fluid secretion resulting from exposure to cholera toxin [42], and inhibitors of the cell Toxins 2010, 2  
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surface protease furin have been shown to inhibit the activation of protective antigen [43]. To our 
knowledge, this is the first report utilizing a high-throughput screen to identify small molecule 
inhibitors of a bacterial pore-forming toxin. 
The compounds we focused on in the present study inhibited the activity of the ε-toxin as 
determined by one or more distinct assays. Inhibition by the three compounds appeared to be specific 
to ε-toxin, as none of the compounds inhibited the activity of aerolysin (data not shown). Aerolysin is 
another pore-forming toxin, structurally similar to ε-toxin, but does not exhibit significant amino acid 
sequence similarity to ε-toxin [44,45]. Informatics searches of the three compounds revealed that 
compound II was active in a variety of different HTS assays, including an HTS to identify inhibitors of 
Shiga toxin (PubChem), an HTS to identify inhibitors of Sentrin-specific proteases 6 and 8 (SENP6 
and SENP8, PubChem), and an ion channel in Plasmodium (ChemBank) [46,47]. Compound III was 
active in an HTS for 14-3-3 protein interaction modulators (PubChem). No previously described 
activity was identified for compound I. 
The activity of an optimized drug often is substantially greater than the activity of the initial hit 
[48,49]. It is therefore not surprising that the compounds studied were not able to provide complete 
protection from the cytotoxic effects of ε-toxin. However, the compounds identified in the   
high-throughput screen and subsequent analyses of structural analogs represent a first step at   
structure-activity analysis. Additional structure-activity analysis is needed to identify inhibitors with 
improved activity. 
We hypothesize that the inhibitors interfere with the toxin pore (by inhibiting ion fluxes through the 
pore that otherwise contribute to cell death) or an unidentified host factor that contributes to   
ε-toxin-induced cytotoxicity. This hypothesis is based on our observation that none of the compounds 
appeared to interfere with binding of the toxin to cells or with toxin oligomerization. In contrast, 
compounds I and II inhibited propidium iodide influx in cells pre-treated with ε-toxin [11,12,22]. 
These results suggest the possibility that one or more refined structures based on the compounds 
identified in the present study may be effective post-exposure therapeutics.  
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